It may soon get crowded at the bargaining table for a Medivation buyout. This morning Bloomberg reported that Amgen is now actively pondering a bid for the biotech. The news follows Sanofi’s $9.3 billion bid as well as Pfizer’s reported interest in making its own offer.
A bidding war would suit Medivation CEO David Hung perfectly. The biotech spurned Sanofi’s $52.50 per share offer and will now get to consider its defensive strategy now that Sanofi has threatened to go hostile and go after its board unless they get serious about negotiating a deal.
There’s no certainty that either Pfizer or Amgen will make an offer for a company that would deliver the prostate cancer drug Xtandi as well as an experimental PARP inhibitor. But every new report of added interest can only add to the pressure on Sanofi to increase its bid. And AstraZeneca as well as Novartis have also been rumored to be among the potential suitors.
Analysts have speculated that Medivation’s price could go all the way to $70 a share, which would provide a big premium for investors. For Hung, who captured the attention of the industry with high-dollar collaborations in cancer as well as Alzheimer’s, extracting the biggest price for the company’s stock could be his last big play at Medivation. A few well placed news stories can only help him on that quest.
By John Carroll
Source: Fierce Biotech
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.